Comparison of the Efficacy and Safety of Kunxian Capsule and Methotrexate for the Treatment of Rheumatoid Arthritis
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 428
- 试验地点
- 16
- 主要终点
- Proportion of patients with ACR 20/50/70
研究概览
简要总结
This is a multicenter, randomized, double blind, double-dummy and controlled clinical trial aimed to compare the clinical efficacy and safety of Kunxian Capsule, a compound of Chinese traditional medicine, and the active comparator,Methotrexate for the treatment of rheumatoid arthritis. The primary end-point is that Kunxian Capsule is not inferior to Methotrexate both in efficacy and safety.
详细描述
This is a prospective, multicenter, randomized, double blind, double-dummy and controlled clinical trial.The goal is to compare the clinical efficacy and safety of Kunxian Capsule, a compound of 4 ingredients of Chinese herb-derived medication, and the active comparator, Methotrexate for the treatment of mild to moderate active rheumatoid arthritis.This study is basically non-inferiority in design, so 428 subjects will be enrolled. All subjects need to fulfill the inclusion criteria and without exclusion criteria. Subjects are randomized into the Kunxian Capsule treatment group and Methotrexate treatment group.The dosage of Kunxian Capsule used in this study is 0.6g twice daily and the methotrexate dosage is 10mg per week. All subjects will take the medication for 24 weeks. Diclofenic is used as the salvage therapy in case patients experience joint pain. The primary end-point is the proportion of patients who could achieve disease remission or low disease activity treated with Kunxian Capsule and Methotrexate. All patients will be followed at week 2,4,12 and 24 after screening. Baseline information for disease activity measures such as DAS28 score,CDAI score, SDAI score, ACR20, ACR50, ACR70 improvement, HAQ score, patient's VAS score for pain, and lab tests such as CRP, ESR, RF, CCP, blood and urine routine tests, liver as well as renal function tests were collected and recorded. All these measures are performed at each follow-up visit except RF and CCP. In addition, any adverse events or withdrawal happened during each visit will be recorded for data analysis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 40 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who understand the study protocol and sign the informed consent；
- •Fulfill the 1987 or 2010 ACR classification criteria for RA；
- •Male or female patients, age ranged from 40-70;
- •Male or female who do not plan to have more child,or per-menopausal or menopausal women；
- •Patients with mild or moderate disease activity, ie, whose DAS28 ranged from 3.2-5.1（ie, ESR>28mm/h，or patients who have 1-5 swollen joints as well as 1-5 tender joints）；
- •Without severe systemic disorders,such as severe pericardial effusion,pulmonary interstitial fibrosis,renal tubual acidosis,atrophic gastritis,autoimmune liver disease etc.
- •Not included in any drug trial 1 month before enrollment
排除标准
- •Pregnant woman or women who are preparing to pregnant or breast feeding；
- •Patients with active liver diseases or elevated liver enzymes eg, the ALT and/or AST is higher than 1.5 of the upper limit of normal range;
- •Patients with renal function abnormality,eg,serum creatinin higher than the upper limit of normal range；
- •White blood cell count less than 3.0×109/L，or with anemia(hemoglobin level lower than 80g/L），or platelet count less than 80×109/L，or with other hematological diseases;
- •Patients with chronic gastrointestinal diseases；
- •Patients with un-controlled hypertension,metabolic diseases such as diabetes;
- •History of malignant tumor or has malignant tumor at present;
- •With acute and/or chronic contagious diseases；
- •Severe arrhythmia on ECG test;
- •History of adverse reaction with Kunxian capsule,or Tripterygium wilfordii Hook F.,methotrexate or medications contain kunminshanhaitang ingredient；
- •History of psychiatric diseases or alcoholism or drug abuse；
- •Having been diagnosed to have systemic rheumatic diseases;
- •Ever taken immunosuppressive agents or biological agents or Tripterygium wilfordii Hook F or medications contain kunminshanhaitang ingredient in recent 3 months；
- •Had ever taken methotrexate or Kunxian capsule for more than 12 weeks but could not control the arthritis under remission；
- •With other conditions that are considered to be inconsistent with the inclusion criteria according to the investigators.
研究组 & 干预措施
Kunxian capsule group
Intervention:
Drug: Kunxian 2 capsules BID taken by mouth for 24 weeks. Kunxian capsule is composed of 4 ingredients: Tripterygium wilfordii Hook F 300mg, extracts from Gouqizi,Tusizi and yinyanghuo.
干预措施: Kunxian Capsule (Drug)
Methotrexate group
Intervention:
Drug: Methotrexate tablet 10mg taken by mouth every week for 24 weeks.
干预措施: Methotrexate (Drug)
结局指标
主要结局
Proportion of patients with ACR 20/50/70
时间窗: 24 weeks from baseline
the percentage of patients who have ACR 20,50 and 70 treatment response after treated with Kunxian Capsule and Methotrexate for 24 weeks
次要结局
- Proportion of patients whose DAS28 score less than 2.6 or 3.2 after treated with Kunxian Capsule and Methotrexate(24 weeks from baseline)
- Proportion of patients with adverse events in the Kunxian Capsule treatment group(24 weeks from baseline)
研究者
Xinping Tian
MD
Chinese SLE Treatment And Research Group